Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -9.59%21 Receivables Turnover is 1.46 as of Sep. 2025. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 116 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 71.55% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cellyan Biotechnology Co's Revenue for the
six
months ended in Sep. 2025 was $7.14 Mil. Cellyan Biotechnology Co's average Accounts Receivable for the
six
months ended in Sep. 2025 was $4.87 Mil.
Hence, Cellyan Biotechnology Co's Receivables Turnover for the
six
months ended in Sep. 2025 was 1.46.
Cellyan Biotechnology Co (NAS:HKPD) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cellyan Biotechnology Co Receivables Turnover Related Terms
Cellyan Biotechnology Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cellyan Biotechnology Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co Receivables Turnover Chart
HKPD vs COSM, SNYR, YI: Receivables Turnover Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a Receivables Turnover of 1.46 as of Sep. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cellyan Biotechnology Co and its competitors. According to the industry distribution chart, Cellyan Biotechnology Co ranks #83 out of 116 companies in the Medical Distribution industry, placing it in the top 71.6%.
Is Cellyan Biotechnology Co's Receivables Turnover too high?
Cellyan Biotechnology Co's current Receivables Turnover is 1.46. The Medical Distribution industry median Receivables Turnover is 4.55. Cellyan Biotechnology Co's value of 1.46 is 67.9% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #83 out of 116 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Receivables Turnover compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #83 out of 116 companies for Receivables Turnover. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Receivables Turnover is 4.55. Cellyan Biotechnology Co's value of 1.46 is 67.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.55, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Receivables Turnover of 1.46 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Receivables Turnover is 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Receivables Turnover of 1.46. The current Receivables Turnover is 1.46 and 67.9% below the Medical Distribution industry median of 4.55. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Receivables Turnover is 1.46 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
